Read by QxMD icon Read


Chai Hong Rim, Jinsil Seong
In oncologic practice, treatment guidelines provide appropriate treatment strategies based on evidence. Currently, many guidelines are used, including those of the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL-EORTC), National Comprehensive Cancer Network (NCCN), Asia-Pacific Primary Liver Cancer Expert (APPLE), and Korean Liver Cancer Study Group and National Cancer Centre (KLCSG-NCC). Although radiotherapy is commonly used in clinical practice, some guidelines do not accept it as a standard treatment modality...
September 2016: Radiation Oncology Journal
Carlo Sposito, Stefano Di Sandro, Federica Brunero, Vincenzo Buscemi, Carlo Battiston, Andrea Lauterio, Marco Bongini, Luciano De Carlis, Vincenzo Mazzaferro
AIM: To develop a prognostic scoring system for overall survival (OS) of patients undergoing liver resection (LR) for hepatocellular carcinoma (HCC). METHODS: Consecutive patients who underwent curative LR for HCC between 2000 and 2013 were identified. The series was randomly divided into a training and a validation set. A multivariable Cox model for OS was fitted to the training set. The beta coefficients derived from the Cox model were used to define a prognostic scoring system for OS...
September 28, 2016: World Journal of Gastroenterology: WJG
(no author information available yet)
No abstract text is available yet for this article.
September 12, 2016: Journal of Hepatology
W-K Seto, J Fung, K-S Cheung, L-Y Mak, R W H Hui, K S H Liu, C-L Lai, M-F Yuen
BACKGROUND: Factors influencing changes in liver stiffness measurements during long-term nucleoside analogue therapy for chronic hepatitis B (CHB) have not been thoroughly investigated. AIM: To identify determinants of on-treatment fibrosis regression in CHB. METHODS: We performed follow-up liver stiffness and controlled attenuation parameter measurements on nucleoside analogue-treated CHB patients with severe liver fibrosis, according to EASL-ALEH criteria, diagnosed by transient elastography in 2006-2008...
November 2016: Alimentary Pharmacology & Therapeutics
Florian Nima Fleckenstein, Rüdiger Egbert Schernthaner, Rafael Duran, Jae Ho Sohn, Sonia Sahu, Karen Marshall, MingDe Lin, Bernhard Gebauer, Julius Chapiro, Riad Salem, Jean-François Geschwind
PURPOSE: Liver metastases from renal cell carcinoma (RCC) are not uncommon in the course of disease. However, data about tumor response to intraarterial therapy (IAT) are scarce. This study assessed whether changes of enhancing tumor volume using quantitative European Association for the Study of the Liver (qEASL) on magnetic resonance imaging (MRI) and computed tomography (CT) can evaluate tumor response and predict overall survival (OS) early after therapy. METHODS AND MATERIALS: Fourteen patients with liver metastatic RCC treated with IAT (transarterial chemoembolization: n= 9 and yttrium-90: n= 5) were retrospectively included...
October 2016: Translational Oncology
Fatemeh Sobhani, Chunmiao Xu, Emi Murano, Li Pan, Neda Rastegar, Ihab R Kamel
OBJECTIVE: To evaluate the value of anatomic and volumetric functional magnetic resonance imaging (MRI) in early assessment of response to trans-arterial chemoembolization (TACE) in hypovascular liver metastases. METHODS: This retrospective study included 52 metastatic lesions (42 targeted and 10 non-targeted) in 17 patients who underwent MRI before and early after TACE. Two reviewers reported response by anatomic criteria (Response Evaluation Criteria in Solid Tumor [RECIST], modified RECIST [mRECIST], and European Association for the Study of Liver Disease [EASL]) and functional criteria (volumetric apparent diffusion coefficient and contrast enhancement)...
August 2016: Translational Oncology
Ashley A Weiner, Jeffrey Olsen, Daniel Ma, Pawel Dyk, Todd DeWees, Robert J Myerson, Parag Parikh
BACKGROUND AND PURPOSE: To report outcomes and toxicities of a single-institution phase I/II study of stereotactic body radiotherapy (SBRT) in the treatment of unresectable hepatocellular cancer (HCC) and intrahepatic cholangiocarcinoma (IHC). MATERIALS AND METHODS: Patients with Child-Pugh score less than 8 were eligible. A total of 32 lesions in 26 patients were treated with SBRT. Kaplan-Meier survival analysis was performed. Toxicities were graded by CTCAEv4 criteria and response was scored by EASL guidelines...
August 23, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Xiaolong Qi, Xin Zhang, Zhijia Li, Jialiang Hui, Yi Xiang, Jinjun Chen, Jianbo Zhao, Jing Li, Fu-Zhen Qi, Yong Xu
Hepatic venous pressure gradient (HVPG) measurement provides independent prognostic value in patients with cirrhosis, and the prognostic and predictive role of HVPG in hepatocellular carcinoma (HCC) also has been explored. The management of HCC is limited to the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines that consider that HVPG≥10 mmHg to be a contraindication for hepatic resection (HR), otherwise other treatment modalities are recommended...
August 23, 2016: Oncotarget
Marco Dioguardi Burgio, Maxime Ronot, Onorina Bruno, Claire Francoz, Valérie Paradis, Laurent Castera, François Durand, Olivier Soubrane, Valérie Vilgrain
Aim The purpose was to compare the results of RECIST, mRECIST, and EASL criteria for the evaluation of tumor necrosis in patients treated with transarterial chemoembolization (TACE) before liver transplantation for hepatocellular carcinoma (LT-HCC). Methods Response to treatment was evaluated on CT scan by 2 independent readers based on RECIST, mRECIST, and EASL criteria, and compared to tumor necrosis assessed by explant pathology. Necrosis was defined as major when >90%. Factors associated with major necrosis were tested by multivariate analysis...
August 20, 2016: Liver Transplantation
Etienne Garin, Yan Rolland, Marc Pracht, Samuel Le Sourd, Sophie Laffont, Habiba Mesbah, Laure-Anne Hamont, Laurence Lenoir, Tanguy Rohou, Vanessa Brun, Julien Edeline
Efficacy of radioembolization is derived from radioinduced damage, whereas tumor dosimetry is not considered as yet in prospective clinical trials OBJECTIVES: This study evaluates the impact of tumor dose (TD), based on (99m) Tc macroaggregated albumin (MAA) quantification, on response and overall survival (OS) MATERIALS AND METHODS: We consecutively included 85 patients with HCC treated with (90) Y-loaded glass microspheres. TD was calculated using a quantitative analysis of the MAA SPECT/CT. Responses were assessed after 3 months using the EASL criteria...
August 11, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
N D Yushchuk, O O Znoyko, K R Dudina, A N Kozina, O V Kalinina
The review gives the data available in the literature in the efficiency of treatment in patients with chronic hepatitis C infected with hepatitis C virus.(HCV) recombinants, by applying various antiviral therapy regimens. The low efficiency of treatment with- pegylated interferons (PEG IFN) + ribavirin (RIB) and sofosburin (SOF) +RIB in this patient group (a sustained virologic response was achieved in 22 and 30.7%, respectively) compared with the efficiency of treatment (87-97 and 83-97%, respectively) inpatients infected with HCV genotype 2 does not allow the 2015 EASL HCV genotype 2 treatment regimens to be used in...
2016: Terapevticheskiĭ Arkhiv
Olaguoke Akinwande, Charles Scoggins, Robert C G Martin
AIM: To report our early experience on the feasibility and safety of 70-150 μm drug-eluting beads loaded with irinotecan (M1-DEBIRI) for treating unresectable hepatic colorectal metastases. PATIENTS AND METHODS: An Institutional Review Board-approved, prospectively maintained, multi-institutional registry was evaluated from 2/2009 to 8/2013. Fifteen consecutive patients presenting with liver-dominant metastatic colorectal cancer were treated with M1-DEBIRI. Kaplan-Meier statistics was used to evaluate hepatic progression-free-survival and overall survival...
July 2016: Anticancer Research
Cristina Mosconi, Annagiulia Gramenzi, Salvatore Ascanio, Alberta Cappelli, Matteo Renzulli, Cinzia Pettinato, Giovanni Brandi, Fabio Monari, Alessandro Cucchetti, Franco Trevisani, Rita Golfieri
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a rapidly progressing malignancy; only a minority of the tumours can be resected and the palliative regimens have shown limited success. The aim of this study was to assess overall survival (OS), tumour response and the safety of radioembolization with yttrium-90 ((90)Y-TARE) in patients with unresectable/recurrent ICC. METHODS: Survival was calculated from the date of the (90)Y-TARE procedure. Target and overall Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) and European Association for the Study of the Liver (EASL)-measuring delayed-phase contrast enhancement-treatment responses were assessed at 3 months...
July 26, 2016: British Journal of Cancer
Jae-Jun Shim, In Hwan Oh, Sang Bae Kim, Jung Wook Kim, Chang Kyun Lee, Jae Young Jang, Ju-Seog Lee, Byung-Ho Kim
Background/Aims: The benefit of oral antiviral therapy in preventing hepatocellular carcinoma (HCC) in the general population is not well understood. We used a novel prediction method to estimate the risk of HCC in the Korean population based on various treatment guidelines. Methods: The 5-year risk of HCC following antiviral therapy was calculated using an HCC risk prediction model. A virtual cohort that represented Koreans (>40 years old) with chronic hepatitis B virus (HBV) infection was established using the fifth National Health and Nutrition Examination Survey...
June 13, 2016: Gut and Liver
Vicente Arroyo, Richard Moreau, Patrick S Kamath, Rajiv Jalan, Pere Ginès, Frederik Nevens, Javier Fernández, Uyen To, Guadalupe García-Tsao, Bernd Schnabl
The definition of acute-on-chronic liver failure (ACLF) remains contested. In Europe and North America, the term is generally applied according to the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium guidelines, which defines this condition as a syndrome that develops in patients with cirrhosis and is characterized by acute decompensation, organ failure and high short-term mortality. One-third of patients who are hospitalized for acute decompensation present with ACLF at admission or develop the syndrome during hospitalization...
2016: Nature Reviews. Disease Primers
Jean-Paul Cervoni, Àlex Amorós, Rafael Bañares, Jose Luis Montero, German Soriano, Delphine Weil, Richard Moreau, Marco Pavesi, Thierry Thévenot, Vincent Di Martino
BACKGROUND/AIMS: The variations in C-reactive protein (CRP) levels have been reported to have prognostic significance in decompensated cirrhotic patients. We aimed to provide an external validation of a prognostic model combining model for end-stage liver disease (MELD) and 'sustained high CRP levels' as main variables and to optimize the model to the context of liver transplantation by focusing on 3-month mortality with no consideration of severe chronic extrahepatic diseases. PATIENTS AND METHODS: Data from cirrhotic patients enrolled in the CANONIC study were collected...
September 2016: European Journal of Gastroenterology & Hepatology
Chang Zhao, Liwei Fan, Feng Qi, Shengqiu Ou, Lei Yu, Xiaoyu Yi, Bingqiang Ni, Zhiyong Zheng, Jianxun Lu, Chengwen Zhang, Changsheng Chen, Xiong Lu, Lin Cheng, Tianlian Hu, Yilong Ma
Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare. In this report, we aim to assess the efficacy and safety of raltitrexed plus oxaliplatin (OXA)-based transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (uHCC). Patients with uHCC were recruited from multi-centers in China and assigned randomly to raltitrexed+OXA-based (n=76), fluorouracil+OXA-based (n=76), and doxorubicin+OXA-based (n=75) TACE treatment...
August 2016: Anti-cancer Drugs
A Majumdar, M T Kitson, S K Roberts
BACKGROUND: The burden of HCV cirrhosis is high and projected to increase significantly over the next decade. While interferon therapy is problematic in HCV cirrhosis, the era of direct-acting anti-viral (DAA) therapy provides effective treatment for patients with cirrhosis. AIM: To systematically review the results of DAA therapy to date in patients with HCV cirrhosis, and highlight the ongoing challenges for DAA therapy in this population. METHODS: A structured Medline search was conducted to obtain phase II and III HCV trials in patients with cirrhosis...
June 2016: Alimentary Pharmacology & Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
July 2016: Journal of Hepatology
(no author information available yet)
No abstract text is available yet for this article.
August 2016: Journal of Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"